Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912559110> ?p ?o ?g. }
- W2912559110 endingPage "569" @default.
- W2912559110 startingPage "553" @default.
- W2912559110 abstract "Introduction: Omalizumab is a recombinant monoclonal anti-IgE antibody approved in the US as add-on treatment in moderate-to-severe allergic asthma (in severe allergic asthma [SAA] in Europe). A 2016 review of 24 real-world effectiveness studies in SAA published between 2008–2015 concluded that omalizumab was associated with significant improvements in objective and subjective outcomes with benefits extending beyond 2 years. Several new real-world studies have been published since, bringing the total to 42 studies.Areas covered: This systematic review of 42 studies published since 2008 updates and extends the 2016 review on the real-word evidence on omalizumab in SAA. It offers greater granularity as to time windows within which outcomes are reported and includes studies extending well beyond 4 years post omalizumab initiation.Expert commentary: This review firmly establishes the short-term effectiveness of omalizumab in adolescent and adult patients with SAA at 1 year, and provides strong evidence of long-term effectiveness up to 4 years and emergent evidence of effectiveness beyond 4 years. In the aggregate, these 42 studies underscore the long-term effectiveness of omalizumab in terms of: reducing exacerbations and symptoms, achieving asthma control, improving lung function, enhancing quality of life, decreasing emergency department visits and hospitalizations, and promoting concomitant medication-sparing." @default.
- W2912559110 created "2019-02-21" @default.
- W2912559110 creator A5006031044 @default.
- W2912559110 creator A5011672680 @default.
- W2912559110 creator A5031658471 @default.
- W2912559110 creator A5044142108 @default.
- W2912559110 creator A5088930342 @default.
- W2912559110 creator A5090261710 @default.
- W2912559110 date "2019-02-14" @default.
- W2912559110 modified "2023-10-12" @default.
- W2912559110 title "Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018" @default.
- W2912559110 cites W12465354 @default.
- W2912559110 cites W1606609712 @default.
- W2912559110 cites W1967215794 @default.
- W2912559110 cites W1974381613 @default.
- W2912559110 cites W1982141273 @default.
- W2912559110 cites W1985017750 @default.
- W2912559110 cites W1985951914 @default.
- W2912559110 cites W1986966401 @default.
- W2912559110 cites W1991956558 @default.
- W2912559110 cites W1994497060 @default.
- W2912559110 cites W1998852126 @default.
- W2912559110 cites W1999211886 @default.
- W2912559110 cites W1999291709 @default.
- W2912559110 cites W2007492002 @default.
- W2912559110 cites W2010604137 @default.
- W2912559110 cites W2012008961 @default.
- W2912559110 cites W2017866305 @default.
- W2912559110 cites W2018515580 @default.
- W2912559110 cites W2024939003 @default.
- W2912559110 cites W2026636141 @default.
- W2912559110 cites W2029319906 @default.
- W2912559110 cites W2029587541 @default.
- W2912559110 cites W2030415090 @default.
- W2912559110 cites W2031117019 @default.
- W2912559110 cites W2031657862 @default.
- W2912559110 cites W2034349740 @default.
- W2912559110 cites W2034499139 @default.
- W2912559110 cites W2037071616 @default.
- W2912559110 cites W2040565769 @default.
- W2912559110 cites W2051331973 @default.
- W2912559110 cites W2053967304 @default.
- W2912559110 cites W2060015303 @default.
- W2912559110 cites W2064671047 @default.
- W2912559110 cites W2064681544 @default.
- W2912559110 cites W2065071227 @default.
- W2912559110 cites W2074119105 @default.
- W2912559110 cites W2084213720 @default.
- W2912559110 cites W2087529838 @default.
- W2912559110 cites W2088171972 @default.
- W2912559110 cites W2093655113 @default.
- W2912559110 cites W2098408173 @default.
- W2912559110 cites W2099211356 @default.
- W2912559110 cites W2105060822 @default.
- W2912559110 cites W2105239752 @default.
- W2912559110 cites W2107486803 @default.
- W2912559110 cites W2120948675 @default.
- W2912559110 cites W2125119017 @default.
- W2912559110 cites W2134142650 @default.
- W2912559110 cites W2137025442 @default.
- W2912559110 cites W2137373998 @default.
- W2912559110 cites W2137404654 @default.
- W2912559110 cites W2151135346 @default.
- W2912559110 cites W2156528640 @default.
- W2912559110 cites W2161374186 @default.
- W2912559110 cites W2161602728 @default.
- W2912559110 cites W2192072888 @default.
- W2912559110 cites W2228200001 @default.
- W2912559110 cites W2331277307 @default.
- W2912559110 cites W2343336085 @default.
- W2912559110 cites W2397424022 @default.
- W2912559110 cites W2473370573 @default.
- W2912559110 cites W2481291932 @default.
- W2912559110 cites W2516173034 @default.
- W2912559110 cites W2531920927 @default.
- W2912559110 cites W2532769566 @default.
- W2912559110 cites W2581649500 @default.
- W2912559110 cites W2601782539 @default.
- W2912559110 cites W2610654869 @default.
- W2912559110 cites W2613362962 @default.
- W2912559110 cites W2616336702 @default.
- W2912559110 cites W2738559968 @default.
- W2912559110 cites W2742653556 @default.
- W2912559110 cites W2753143024 @default.
- W2912559110 cites W2772872092 @default.
- W2912559110 cites W2783917457 @default.
- W2912559110 cites W2790269034 @default.
- W2912559110 cites W2791719145 @default.
- W2912559110 cites W2803625106 @default.
- W2912559110 cites W2810251370 @default.
- W2912559110 cites W2888142747 @default.
- W2912559110 cites W2901940756 @default.
- W2912559110 cites W2981693076 @default.
- W2912559110 cites W4211182003 @default.
- W2912559110 doi "https://doi.org/10.1080/1744666x.2019.1574571" @default.
- W2912559110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30763137" @default.
- W2912559110 hasPublicationYear "2019" @default.
- W2912559110 type Work @default.